Salas-Benito Diego, Vercher Enric, Conde Enrique, Glez-Vaz Javier, Tamayo Ibon, Hervas-Stubbs Sandra
Oncology Department, University of Navarra Clinic, University of Navarra, Navarra, Spain.
Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
EJC Suppl. 2020 Aug 22;15:56-66. doi: 10.1016/j.ejcsup.2019.12.002. eCollection 2020 Aug.
The standard first-line therapy for ovarian cancer is a combination of surgery and carboplatin/paclitaxel-based chemotherapy. Patients with longer survival and improved response to chemotherapy usually present T-cell inflamed tumours. The presence of tumour-infiltrating T cells (TILs) notably varies among the different subtypes of ovarian tumours, being highest in high-grade serous ovarian carcinoma, intermediate in endometrioid tumours, and lowest in low-grade serous, mucinous and clear cell tumours. Interestingly, the presence of TILs is often accompanied by a strong immunosuppressive tumour environment. A better understanding of the immune response against ovarian cancer and the tumour immune evasion mechanisms will enable improved prognostication, response prediction and immunotherapy of this disease. This article provides an overview of some ovarian cancer cell features relevant for antitumour response, such as tumour-associated antigens, including neoantigens, expression of inhibitory molecules, and other mechanisms of immune evasion. Moreover, we describe relevant immune cell types found in epithelial ovarian tumours, including T and B lymphocytes, regulatory T cells, natural killer cells, tumour-associated macrophages, myeloid-derived suppressor cells and neutrophils. We focus on how these components influence the burden of the tumour and the clinical outcome.
卵巢癌的标准一线治疗方案是手术联合以卡铂/紫杉醇为基础的化疗。生存期较长且对化疗反应较好的患者通常表现为T细胞炎症性肿瘤。肿瘤浸润性T细胞（TILs）的存在在不同亚型的卵巢肿瘤中差异显著，在高级别浆液性卵巢癌中最高，在子宫内膜样肿瘤中居中，在低级别浆液性、黏液性和透明细胞肿瘤中最低。有趣的是，TILs的存在往往伴随着强大的免疫抑制肿瘤环境。更好地了解针对卵巢癌的免疫反应和肿瘤免疫逃逸机制将有助于改善该疾病的预后、反应预测和免疫治疗。本文概述了一些与抗肿瘤反应相关的卵巢癌细胞特征，如肿瘤相关抗原（包括新抗原）、抑制性分子的表达以及其他免疫逃逸机制。此外，我们描述了上皮性卵巢肿瘤中发现的相关免疫细胞类型，包括T和B淋巴细胞、调节性T细胞、自然杀伤细胞、肿瘤相关巨噬细胞、髓源性抑制细胞和中性粒细胞。我们重点关注这些成分如何影响肿瘤负担和临床结果。
